Kelly D Getz, PhD, MPH

faculty photo
Assistant Professor of Epidemiology in Biostatistics and Epidemiology
Assistant Professor of Epidemiology (tenure track), Perelman School of Medicine at The University of Pennsylvania
Investigator, Center for Real-world Evidence on the Effectiveness and Safety of Therapeutics (CREST), Perelman School of Medicine at The University of Pennsylvania
Member, Cancer Control Program, Abramson Cancer Center
Senior Scholar, Center for Clinical Epidemiology & Biostatistics, Perelman School of Medicine at The University of Pennsylvania
Member, Normal & Malignant Hematopoiesis Research Affinity Group (NMH-RAG), CHOP Research Institute
Elected Member, Medical Faculty Senate, Perelman School of Medicine at the University of Pennsylvania
Department: Biostatistics and Epidemiology

Contact information
423 Guardian Drive
909 Blockley Hall
Philadelphia, PA 19104
Office: 215-746-1969
Education:
BS (Biology)
Millersville University, 1997.
MPH (Epidemiology)
Boston University School of Public Health, 2009.
PhD (Epidemiology)
Boston University School of Public Health, 2014.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

My research interests are broadly focused on the treatment and supportive care of children and young adults with cancer, with the goal of understanding and balancing therapeutic benefits and toxicity risks. I have a specific interest in the emerging field of cardio-oncology with a focus on earlier detection of the cardiotoxic side effects of cancer treatments, and mitigating cardiac disease as a barrier to effective cancer therapy. I also have an interest in identifying and reducing disparities in the treatment and outcomes of pediatric cancers.

Selected Publications

Molina JC, Li Y, Otto WR, Miller TP, Getz KD, Mccoubrey C, Ramos M, Krause E, Cao L, Gramatges MM, Rabin K, Scheurer M, Elgarten CW, Myers RM, Seif AE, Fisher BT, Shah NN, Aplenc R.: Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy. Pediatr Blood Cancer 70(1): e30062, Jan 2023.

Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy: Molina JC, Li Y, Otto WR, Miller TP, Getz KD, Mccoubrey C, Ramos M, Krause E, Cao L, Gramatges MM, Rabin K, Scheurer M, Elgarten CW, Myers RM, Seif AE, Fisher BT, Shah NN, Aplenc R. Pediatr Blood Cancer 70(1): e30062, Jan 2023.

Demissei BG, Vedage NA, Hubbard RA, Smith AM, Chung J, Lefebvre B, Getz KD, Thavendiranathan P, Narayan HK, Ky B. : Longitudinal Right Ventricular Systolic Function Changes in Breast Cancer Patients Treated With Cardiotoxic Cancer Therapy. JACC CardioOncol 4(4): 552-4, Nov 2022.

Newman H, Li Y, Liu H, Myers RM, Tam V, DiNofia A, Wray L, Rheingold SR, Callahan C, White C, Baniewicz D, Winestone LE, Kadauke S, Diorio C, June CH, Getz K, Aplenc R, Teachey DT, Maude SL, Grupp SA, Bona K, Barz Leahy A.: Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy Blood Nov 2022 Notes: Epub ahead of print.

Demissei BG, Vedage NA, Hubbard RA, Smith AM, Chung J, Lefebvre B, Getz KD, Thavendiranathan P, Narayan HK, Ky B.: Longitudinal Right Ventricular Systolic Function Changes in Breast Cancer Patients Treated With Cardiotoxic Cancer Therapy. JACC CardioOncol 4: 552-554, Nov 2022.

Newman H, Li Y, Liu H, Myers RM, Tam V, DiNofia A, Wray L, Rheingold SR, Callahan C, White C, Baniewicz D, Winestone LE, Kadauke S, Diorio C, June CH, Getz K, Aplenc R, Teachey DT, Maude SL, Grupp SA, Bona K, Barz Leahy A.: Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. Blood Nov 2022.

Li Y, Sun L, Burstein DS, Getz KD.: Considerations of Competing Risks Analysis in Cardio-Oncology Studies: JACC CardioOncology State-of-the-Art Review. JACC CardioOncol 4(3): 287-301, Sep 2022.

Li Y, Sun L, Burstein DS, Getz KD.: Considerations of Competing Risks Analysis in Cardio-Oncology Studies: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 4: 287-301, Sep 2022.

Miller TP, Getz KD, Li Y, Demissei BG, Adamson PC, Alonzo TA, Burrows E, Cao L, Castellino SM, Daves MH, Fisher BT, Gerbing R, Grundmeier RW, Krause EM, Lee J, Lupo PJ, Rabin KR, Ramos M, Scheurer ME, Wilkes JJ, Winestone LE, Hawkins DS, Gramatges MM, Aplenc R.: Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group. Lancet Haematol 9(9): e678-e688, Sep 2022.

Miller TP, Getz KD, Li Y, Demissei BG, Adamson PC, Alonzo TA, Burrows E, Cao L, Castellino SM, Daves MH, Fisher BT, Gerbing R, Grundmeier RW, Krause EM, Lee J, Lupo PJ, Rabin KR, Ramos M, Scheurer ME, Wilkes JJ, Winestone LE, Hawkins DS, Gramatges MM, Aplenc R. : Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group. Lancet Haematol 9(9): e678-e688, Sep 2022.

back to top
Last updated: 01/13/2023
The Trustees of the University of Pennsylvania